DECIBEL THERAPEUTICS INC (DBTX)

US24343R1068 - Common Stock

4.91  -0.04 (-0.81%)

After market: 4.91 0 (0%)

Fundamental Rating

2

Taking everything into account, DBTX scores 2 out of 10 in our fundamental rating. DBTX was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of DBTX have multiple concerns. DBTX does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DBTX has reported negative net income.
In the past year DBTX has reported a negative cash flow from operations.
In the past 5 years DBTX reported 4 times negative net income.
In the past 5 years DBTX always reported negative operating cash flow.

1.2 Ratios

DBTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DBTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for DBTX remains at a similar level compared to 1 year ago.
DBTX has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -4.40, we must say that DBTX is in the distress zone and has some risk of bankruptcy.
DBTX's Altman-Z score of -4.40 is on the low side compared to the rest of the industry. DBTX is outperformed by 64.40% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that DBTX is not too dependend on debt financing.
The Debt to Equity ratio of DBTX (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.4
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

DBTX has a Current Ratio of 3.03. This indicates that DBTX is financially healthy and has no problem in meeting its short term obligations.
DBTX's Current ratio of 3.03 is on the low side compared to the rest of the industry. DBTX is outperformed by 70.53% of its industry peers.
A Quick Ratio of 3.03 indicates that DBTX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.03, DBTX is not doing good in the industry: 68.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.03
Quick Ratio 3.03

More info and screens

3

3. Growth

3.1 Past

The earnings per share for DBTX have decreased by -9.05% in the last year.
EPS 1Y (TTM)-9.05%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-7.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 12.33% on average over the next years. This is quite good.
DBTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 83.11% yearly.
EPS Next Y-15%
EPS Next 2Y-4.16%
EPS Next 3Y9.38%
EPS Next 5Y12.33%
Revenue Next Year-100%
Revenue Next 2Y11.8%
Revenue Next 3Y-25.99%
Revenue Next 5Y83.11%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.16%
EPS Next 3Y9.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DBTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DECIBEL THERAPEUTICS INC

NASDAQ:DBTX (9/22/2023, 7:00:01 PM)

After market: 4.91 0 (0%)

4.91

-0.04 (-0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap123.39M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.03
Quick Ratio 3.03
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-9.05%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y